From vulnerable plaque to blood healthy therapy

Area of Science:

• Cardiovascular Medicine
• Thrombosis Research
• Vascular Biology

Background:

• Cardiovascular atherosclerotic disease is a leading global cause of mortality.
• Vulnerable plaques, characterized by intra-plaque hemorrhage or thin fibrous caps with large lipid cores, are associated with plaque rupture.
• Predicting acute events from plaque rupture alone is challenging due to the complex interplay of factors.

Purpose of the Study:

• To explore the role of blood factors in bridging plaque rupture to clinical events.
• To evaluate blood healthy therapy as a potential strategy to mitigate thrombotic risks.
• To investigate therapeutic apheresis for reducing hypercoagulability and thrombosis resistance.

Main Methods:

• Review of current investigations on vulnerable plaque characteristics and rupture.
• Analysis of the role of blood factors, particularly hypercoagulability, in thrombotic events.
• Conceptual exploration of therapeutic apheresis for modulating blood's thrombotic potential.

Main Results:

• Plaque rupture alone is an insufficient predictor of symptomatic events.
• Blood factors, especially those promoting thrombosis, are critical mediators between plaque rupture and clinical sequelae.
• Therapeutic apheresis can decrease blood hypercoagulability.

Conclusions:

• Managing plaque rupture directly is difficult, necessitating alternative strategies.
• Modulating blood's thrombotic propensity is a viable approach to reduce cardiovascular events.
• Blood healthy therapy, via therapeutic apheresis, offers a promising avenue for preventing acute coronary syndrome and stroke.